OWX.F Ypsomed Holding AG
- Market cap
- EUR 5.86B
- P/E
- 32.7x
- P/B
- 6.57x
- ROE
- 29.7%
- Dividend yield
- 1.12%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is OWX.F undervalued?
Graham numberThe Graham number of Ypsomed Holding AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ypsomed Holding AG fundamental analysis
No fundamental analysis for Ypsomed Holding AG yet.
Ypsomed Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, …
Full company profileYpsomed Holding AG financial statements
Ypsomed Holding AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 307M | 337M | 390M | 466M | 454M | 465M | 497M | 548M | 749M | 731M |
| Gross Profit | 85.9M | 103M | 125M | 140M | 156M | 114M | 141M | 220M | 292M | 315M |
| Operating Income | 26.9M | 44.3M | 55.3M | 60.9M | 73.2M | 28.6M | 60.6M | 86.2M | 113M | 246M |
| EBITDA | - | - | - | - | - | - | 137M | 162M | 191M | 326M |
| Net Income | 19.4M | 35.8M | 46.2M | 52.1M | 60.1M | 23.1M | 51.3M | 78.4M | 87.5M | 222M |
| EPS | - | - | - | - | - | 1.82 | 3.76 | 5.74 | 6.41 | 16 |
| Balance Sheet | ||||||||||
| Total Assets | 361M | 389M | 422M | 500M | 588M | 757M | 862M | 1.09B | 1.33B | 1.35B |
| Total Liabilities | 121M | 121M | 120M | 159M | 209M | 364M | 300M | 476M | 651M | 598M |
| Shareholders' Equity | 241M | 268M | 302M | 342M | 379M | 393M | 562M | 618M | 680M | 748M |
| Cash & Short-term Investments | 16.2M | 25.5M | 38.9M | 32.1M | 12.1M | 17.0M | 25.2M | 74.0M | 36.5M | 28.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 41.4M | 76.7M | 75.1M | 53.3M | 59.9M | 85.7M | 130M | 163M | 148M | 307M |
| Capital Expenditure | 17.2M | 25.2M | 27.5M | 51.0M | 107M | 127M | 169M | 195M | 277M | 323M |
| Free Cash Flow | - | - | - | - | - | -41.7M | -39.6M | -32.1M | -129M | -16.3M |
| Ratios | ||||||||||
| ROE | 8.1% | 13.4% | 15.3% | 15.2% | 15.9% | 5.9% | 9.1% | 12.7% | 12.9% | 29.7% |
| ROA | 5.4% | 9.2% | 11.0% | 10.4% | 10.2% | 3.1% | 5.9% | 7.2% | 6.6% | 16.5% |
| Net Profit Margin | 6.3% | 10.6% | 11.9% | 11.2% | 13.3% | 5.0% | 10.3% | 14.3% | 11.7% | 30.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ypsomed Holding AG dividends
- Dividend yield
- 1.12%
- Forward dividend
- 4.78 EUR
- Payout ratio
- 13.5%
- Ex-dividend date
- Jul 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | CHF 30.0M | 2.20 | 13.5% |
| 2025 | CHF 27.3M | 2.00 | 31.2% |
| 2024 | CHF 17.7M | 1.30 | 22.6% |
| 2023 | CHF 8.19M | 0.60 | 16.0% |
| 2022 | CHF 14.7M | 1.16 | 63.5% |
| 2019 | EUR 17.6M | - | 29.3% |
| 2018 | EUR 16.4M | - | 31.5% |
| 2017 | EUR 12.6M | - | 27.3% |
| 2016 | EUR 7.58M | - | 21.2% |
| 2015 | GBP 3.78M | - | 19.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ypsomed Holding AG
- Insiders 69.59%
- Institutions 15.87%
- Public & others 14.54%
- Shares outstanding 13.1M
- Free float 3.51M
Ypsomed Holding AG company profile
- Company name
- Ypsomed Holding AG
- Ticker
- OWX.F
- ISIN
- CH0019396990
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,025
- Fiscal year end
- March
- Address
- Brunnmattstrasse 6, Burgdorf, Switzerland, 3401
- Phone
- 41 34 424 41 11
- Website
- ypsomed.com
About Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Ypsomed Holding AG management
7- Mr. Simon MichelCEO, Member of Executive Board & Member of the Board · born 1977
- Mr. Samuel KunzliChief Financial Officer & Member of Executive Board · born 1984
- Ms. Ulrike BauerChief Business Officer & Member of Executive Board · born 1969
- Mr. Frank MengisCOO, Deputy CEO Member of Executive Board · born 1964
- Mr. Michael ZauggChief Corporate Officer & Member of Executive Board · born 1972
- Dr. Nicolas MeyerChief Legal Officer & Secretary and Member of Executive Board · born 1971
- Sam GhezelbashHead of Investor Relations & M&A